Healthcare Equipment and Supplies
Company Overview of Medafor, Inc.
Medafor, Inc. develops and markets haemostatic products based on engineered biopolymeric microporous particles in the United States and internationally. The company offers AristaAH, an absorbable surgical hemostat product that is used in the control of profuse bleeding in general surgery; FlexiTip, a spray applicator for the management of bleeding or profuse following topical ENT surgical procedures; and TraumaDEX, a topical dressing for the control of severely bleeding wounds from traumatic injuries, including cuts, lacerations, and puncture wounds. The company also provides SafeSeal and MPatcH that are topical adhesive wound dressings for the local management and control of bleeding from v...
2700 Freeway Boulevard
Minneapolis, MN 55430
Founded in 1999
Key Executives for Medafor, Inc.
Compensation as of Fiscal Year 2016.
Medafor, Inc. Key Developments
CryoLife Resolves Patent Litigation with Medafor over Blood-Clotting Agent Perclot
Nov 17 15
CryoLife reported it resolved a patent dispute with CR Bard's (BCR) subsidiary Medafor over blood-clotting agent PerClot. Under the terms of the resolution, both companies agreed to dismiss all claims and waive all appeal rights. CryoLife noted that a preliminary injunction forbidding it to market and sale PerClot in the U.S. will remain in effect until Medafor's related patent expires on Feb. 8, 2019.
CryoLife Provides Update on PerClot Litigation
Mar 12 15
CryoLife, Inc. provided an update on its ongoing litigation with C.R. Bard, Inc. and certain of its subsidiaries regarding PerClot. The U.S. District Court for the District of Delaware has allowed CryoLife's declaratory judgment lawsuit against C.R. Bard's Medafor, Inc. subsidiary to proceed. The Court also granted Medafor's motion for a preliminary injunction with respect to CryoLife's marketing and sale of PerClot Topical in the U.S. CryoLife is currently awaiting the Court's order, which it expects will provide details regarding the scope of the injunction. In April 2014, CryoLife filed a declaratory judgment lawsuit against C.R. Bard and certain of its subsidiaries, including Medafor, requesting that the Court declare that CryoLife's manufacture, use, offer for sale, and sale of PerClot in the U.S. does not and would not infringe Medafor's U.S. Patent No. 6,060,461. In addition CryoLife requested that the Court declare that the claims of the '461 Patent are invalid. In September 2014, Medafor filed a motion for a preliminary injunction against CryoLife.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries